Responses and counting . . .
Each year, GDS consults more than 100,000 people around the world on the way they use drugs. We do this to get to the heart of how, where, when, why and what drugs are being taken. By discussing the findings we aim to make drug use safer, regardless of the legal status of the drug.
Share your story with us and help change the conversation. Because your experience matters.
GDS2018 – exploring losing your drug virginity, drug checking, dark net markets, new drugs, quitting cannabis, alcohol health warning labels, drug purchase, delivery and sharing, MDMA – pills or powders and what the perfect MDMA might look like, ketamine bladder GHB and lots more . . .Launch GDS2018 2017 Findings
GDS 2017 — Key findings! 2017 Global Drug Survey shows UK drug purity leading to spike in A&E admissions
GDS is an efficient approach to gain content rich data that explores diverse health outcomes associated with the use of drugs and alcohol across the population of your country.
GDS can help you add numbers and depth to the findings of more rigorous, though less detailed and smaller, survey findings. Using anonymous on-line research tools, designed and analysed by leading experts in the fields of epidemiology, addiction, criminology, toxicology and sociology GDS has access to drug use data from over 500,000 people from over 50 countries.
The GDS sampling frame allows you to effectively compare population segments - young, old, males, females, gay, straight, clubbers, thin people, obese people, vegetarians, those with a current psychiatric symptoms and diagnoses, students, northerners, southerners. GDS helps you better understand the quantitative dynamics of personal decision-making about drug use, detects regional differences in patterns of drug use and related harm, and informs novel interventions.
GDS creates beautiful data reports, digital health assessment tools and free harm reduction resources that aim to make drug use safer regardless of the legal status of the drug GDS reaches hidden, sentinel and hard to reach populations and puts you on top of emerging drug trends in your country and major cities.
#drugs are very very xxxxx see what @robincarhart thinks here @ProfDavidNutt @MAPS @breakingcon and then about us a… https://t.co/j6Aom81n5DOpen
RT @UCL_CPU: Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial: American Journal of Ps…Open
What’s the Daily Mail going to do with this ? https://t.co/wYNaOIkzIeOpen